These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Bhatt DL; Topol EJ JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650 [TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Lincoff AM; Califf RM; Topol EJ J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948 [TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912 [No Abstract] [Full Text] [Related]
10. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists]. Araujo R; Agustà A Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849 [No Abstract] [Full Text] [Related]
11. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. Tcheng JE Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231 [No Abstract] [Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Leclerc JR Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256 [TBL] [Abstract][Full Text] [Related]
13. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720 [TBL] [Abstract][Full Text] [Related]
14. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
15. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Sabatine MS; Jang IK Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186 [TBL] [Abstract][Full Text] [Related]
16. Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit. Zimarino M; De Caterina R J Cardiovasc Pharmacol; 2004 Mar; 43(3):325-32. PubMed ID: 15076214 [TBL] [Abstract][Full Text] [Related]
17. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related]
19. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us. Chew DP; Moliterno DJ Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119 [TBL] [Abstract][Full Text] [Related]
20. IIb's are not IIb's. Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]